查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465974

胚胎着床前基因检测市场：按技术、产品、程序类型、应用、最终用户 - 2024-2030 年全球预测

Preimplantation Genetic Testing Market by Technology, Offering, Procedure Type, Application, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年胚胎着床前基因检测市场规模为7.284亿美元，2024年将达8.2906亿美元，2030年将达18.8628亿美元，复合年增长率为14.56%。

胚胎着床前基因检测（PGT）是指在胚胎着床前检测影响胚胎的染色体异常的技术。 PGT是一项重要服务，能够在体外受精（IVF）方法中及早发现胚胎着床前胚胎的遗传异常，显着降低将遗传性疾病传给后代的风险并提高成功率。 PGT 的主要应用领域包括识别单发疾病、染色体异常、粒线体疾病以及潜在兄弟姐妹的人类白血球抗原 (HLA) 匹配。由于生活方式的改变以及夫妻选择生育的延迟导致不孕率不断上升，因此需要开发PGT技术。政府促进体外受精治疗的措施正在创造许多扩张机会。然而，与 IVF 治疗和 PGT 程序相关的高成本可能是潜在最终用户的主要阻碍力。围绕 PGT 的伦理问题和 IVF 治疗的有限保险范围阻碍了 PGT 服务的采用。领先的生物技术公司正在迅速加强应对道德和监管挑战，创造考虑道德和伦理因素的技术。次世代定序（NGS）和非侵入性胚胎着床前测试等新方法是新兴技术，为该技术的发展提供了巨大潜力。

主要市场统计
基准年[2023] 7.284 亿美元
预测年份 [2024] 82906万美元
预测年份 [2030] 18.8628亿美元
复合年增长率（%） 14.56%

检测染色体异常和单基因疾病的下一代定序技术取得进展

比较基因组杂合反应(CGH) 已被用来比较两个样本的 DNA 来检测染色体失衡。检测胚胎着床前胚胎的染色体异常，有助于选择健康胚胎进行体外受精。萤光原位杂合反应(FISH) 是一种使用萤光探针来视觉化和绘製细胞内染色体上特定 DNA 序列的技术。可以检测染色体异常，包括非整倍体和易位。次世代定序(NGS) 能够快速且准确地对大量 DNA序列测定，因此成为胚胎着床前基因检测的强大工具。聚合酵素链锁反应(PCR) 是一种广泛使用的分子生物学技术，可扩增特定的 DNA 序列以进行分析和检测单基因疾病。单核苷酸多态性（SNP）评估基因组中单核苷酸水平的变异，用于识别遗传疾病的携带者并评估多因素疾病（包括癌症）的风险。

提供：利用多样化的产品来优化製程条件并获得准确的结果

该设备在 PGT 过程中发挥重要作用，因为它可以对胚胎进行准确、高效的基因筛检。关键设备包括次世代定序仪(NGS)、定量 PCR (qPCR) 系统和萤光原位杂合反应(FISH) 分析仪。 NGS具有高通量定序能力和广泛的检测范围，适合检测单基因和染色体异常。 PGT使用的试剂和耗材由基因检测所需的各种套件、探针、缓衝液、酵素、溶液等组成。探针对于检测特定染色体异常至关重要，缓衝液为最佳扩增条件提供了适当的条件。软体和服务是 PGT 不可或缺的一部分，因为它们可确保基因检测结果的可靠资料管理、分析、解释和报告。偏好围绕着使用者友善的介面、准确的变异检测演算法、用于变异註释的综合资料库、安全的资料储存选项等。

胚胎着床前遗传学诊断（PGD）程序变得普及，降低了遗传疾病的风险。

胚胎着床前遗传学诊断（PGD）是一种专门的程序，可以在植入或怀孕前诊断出胚胎中的基因突变和染色体异常。 PGD​​ 的主要目的是降低某些遗传疾病的风险，如囊肿纤维化、亨廷顿舞蹈症和肌肉萎缩症。胚胎着床前遗传学筛检（PGS），也称为非整倍体染色体胚胎着床前遗传学检测（PGT-A），是在胚胎着床前胚胎中染色体非整倍性或不平衡的情况。透过识别具有正确染色体数量的胚胎，PGS旨在降低流产、死产、唐氏症和其他染色体异常的风险，并增加成功怀孕的机会。

广泛使用胚胎着床前基因检测来治疗应用性非整倍体疾病

非整倍体是一种由于细胞内染色体数量异常而导致唐氏症、爱德华兹氏症候群和帕陶氏症等遗传性疾病的疾病。胚胎着床前非整倍体基因检测（PGT-A）可在胚胎着床前辨识出染色体异常的胚胎，进而增加成功怀孕的机会。透过胚胎着床前基因检测进行性别鑑定，让夫妇选择孩子的性别，以平衡家庭并避免与性别相关的疾病。人类白血球抗原 (HLA) 分型可在干细胞和器官移植过程中匹配供体和受体的组织类型。胚胎着床前HLA型检测可以识别组织学相容的胚胎，并促进患有血液疾病或免疫系统缺陷的兄弟姐妹的成功植入。染色体结构异常涉及染色体结构的变化，包括缺失、重复和重排。此外，X连锁疾病是由X染色体上的基因突变引起的，对男性的影响比女性更严重。

最终用户：医疗研究机构越来越多地采用 PGT，以实现准确诊断和有效治疗

胚胎着床前基因检测广泛应用于各种医疗机构，并在临床研究中取得了成功。合约研究和製造组织 (CRMO) 是在产品开发、製造和商业化中发挥关键作用的关键组织。这些组织更喜欢外包服务，以确保品管、遵守监管标准和成本效率，同时专注于核心能力。同样，冷冻库是在极低的温度下储存精子、卵子和胚胎等生物样本以供将来使用的机构。胚胎着床前基因检测对于冷冻银行至关重要，可确保在体外受精和显微授精等移植程序之前储存样本的遗传活力。医院、诊断实验室和服务供应商正在利用胚胎着床前基因检测技术透过准确的诊断和有效的治疗为患者护理做出贡献。研究机构和学术机构透过尖端研究、技术开发和跨学科合作，在推动胚胎着床前基因检测的创新和进步方面发挥关键作用。这些机构专注于开发下一代定序（NGS）等新技术，以提高胚胎着床前基因检测方法的准确性。

区域洞察

在美洲，由于生活方式的改变和基因检测意识的增强导致不孕率上升，因此对胚胎着床前基因检测（PGT）的需求很高。改善的医疗基础设施和优惠的报销政策使美洲寻求不孕症治疗的夫妇更容易获得 PGT 服务。该地区企业拥有强大的研发能力，政府支持支持该领域的创新。亚洲是 PGT 的主要市场，因为 PGT 服务改善了 IVF 等先进生育技术的提供，扩大了医疗旅游业，并吸引了寻求具有成本效益的治疗选择的外国患者。由于政府对医疗保健研究的资助增加以及 IVF 在欧洲国家普及等因素，欧洲对全球 PGT 市场做出了巨大贡献。此外，围绕基因检测的严格法律规范确保了在进行 PGT 服务时的品管和道德考虑。该地区的主要企业正在为胚胎着床前基因检测实践的技术进步做出重大贡献。

FPNV定位矩阵

FPNV定位矩阵对于评估胚胎着床前基因检测市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对胚胎着床前基因测试市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.胚胎着床前基因检测市场规模及预测为何？

2.在胚胎着床前基因检测市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.胚胎着床前基因检测市场的技术趋势和法规结构是什么？

4.胚胎着床前基因检测市场主要厂商的市场占有率如何？

5. 进入胚胎着床前基因检测市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 胎儿畸形发生率高，需要健康、正常的胚胎移植
      • 全球不孕率上升和生育诊所数量增加
      • 扩大早期诊断方法并增加政府对遗传疾病治疗的支持
    • 抑制因素
      • 与 PGT 相关的限制和风险
    • 机会
      • 胚胎着床前遗传分析领域的技术进展
      • 胚胎着床前基因检测领域的新兴Start-Ups生态系与投资
    • 任务
      • PGT 的道德约束和滥用
  • 市场区隔分析
    • 技术：检测染色体异常和单基因疾病的次世代定序取得进展
    • 我们提供什么：利用各种服务来优化製程条件并获得准确的结果。
    • 步骤：更多采用胚胎着床前遗传学诊断 (PGD) 程序，以降低遗传疾病的风险
    • 应用：胚胎着床前基因检测广泛用于非整倍体疾病
    • 最终用户：医疗保健研究组织越来越多地采用 PGT，以实现准确诊断和有效治疗
  • 市场趋势分析
    • 在美洲部署创新的胚胎着床前遗传解决方案的领先公司和新兴企业
    • 政府的支持措施和不断上升的不孕率强调了亚太地区采用胚胎着床前基因检测。
    • 欧洲越来越多地采用体外受精胚胎着床前基因检测，全球参与者可能在中东和非洲扩张
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章胚胎着床前基因检测市场：依技术分类

  • 比较基因组杂合反应
  • 萤光原位杂合技术
  • 次世代定序
  • 聚合酵素链锁反应
  • 单核苷酸多态性

第七章胚胎着床前基因检测市场：透过提供

  • 装置
  • 试剂/耗材
  • 软体和服务

第八章按程序类型分類的胚胎着床前基因检测市场

  • 胚胎着床前遗传学诊断
  • 胚胎着床前基因筛检

第九章胚胎着床前基因检测市场：依应用分类

  • 非整倍体
  • 性别认同
  • HLA型检测
  • 单基因疾病
  • 染色体结构异常
  • X连锁疾病

第 10 章胚胎着床前基因检测市场：依最终用户分类

  • 委託调查/製造组织
  • 冷冻库
  • 医院、诊断实验室、服务供应商
  • 研究实验室和学术机构

第十一章美洲胚胎着床前基因检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太胚胎着床前基因检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲胚胎着床前基因检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Thermo Fisher 推出 Ion ReproSeq PGT-A套件和 Ion AmpliSeq Ploidy套件
    • Kindbody推出Kindlabs 进行内部基因检测
    • Medicover Genetics 和 FimLab Laboratories 宣布合作在芬兰提供基因检测服务
    • 美国 Fertility 和 Ovation 合併成为领先的 IVF 服务公司，改善生育治疗服务的可近性
    • Eurofins Genoma 宣布推出 niPGT-A，一种非侵入性、免胚胎切片检查的胚胎着床前遗传非整倍体筛检测试
    • GenEmbryomics 推出有史以来最全面的 IVF 基因检测
    • 接受体外受精的新加坡人获得某些类型治疗的新资金
    • 澳洲 Fertilis 融资 200 万美元用于自动化 IVF 胚胎培养

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-030EE48515DA

[192 Pages Report] The Preimplantation Genetic Testing Market size was estimated at USD 728.40 million in 2023 and expected to reach USD 829.06 million in 2024, at a CAGR 14.56% to reach USD 1,886.28 million by 2030.

Preimplantation genetic testing (PGT) refers to technologies used to detect chromosomal abnormalities affecting the embryos before implantation. PGT is a crucial service that allows for early detection of genetic abnormalities in embryos before implantation during in-vitro fertilization (IVF) procedures, significantly reducing the risk of passing on inheritable diseases to offspring and improving IVF success rates. The primary application areas for PGT include identifying monogenic disorders, chromosomal abnormalities, mitochondrial diseases, and human leukocyte antigen (HLA) matching for potential siblings. The rising infertility rates due to lifestyle changes and delayed parenthood choices among couples have necessitated the development of PGT technologies. Government initiatives promoting IVF treatments create numerous expansion opportunities. However, high costs associated with IVF treatments and PGT procedures can be a major deterrent to potential end-users. Ethical concerns surrounding PGT and limited insurance coverage for IVF treatments hinder the adoption of PGT services. Major biotechnology companies are rapidly expanding efforts to combat ethical and regulatory challenges and creating technologies that take moral and ethical issues under consideration. New approaches such as next-generation sequencing (NGS) and non-invasive preimplantation testing are emerging technologies that offer significant potential for the growth of the technology.

KEY MARKET STATISTICS
Base Year [2023] USD 728.40 million
Estimated Year [2024] USD 829.06 million
Forecast Year [2030] USD 1,886.28 million
CAGR (%) 14.56%

Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders

Comparative genomic hybridization (CGH) is adopted for detecting chromosomal imbalances by comparing the DNA of two samples. It can detect chromosomal abnormalities in embryos before implantation and help select healthy embryos for IVF. Fluorescence in situ hybridization (FISH) is a technique that uses fluorescent probes to visualize and map specific DNA sequences on chromosomes within cells. It can detect numerical chromosomal abnormalities, including aneuploidy or translocations. Next-generation sequencing (NGS) is a robust tool for preimplantation genetic testing owing to its ability to sequence large amounts of DNA quickly and accurately. Polymerase chain reaction (PCR) is a widely used molecular biology technique that amplifies specific DNA sequences for analysis and can detect monogenic diseases. Single-nucleotide polymorphism (SNP) evaluates variations at the single-nucleotide level within the genome and is used to identify carriers of inherited diseases or assess the risk of multifactorial disorders, including cancer.

Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results

Instruments play a critical role in the PGT process as they enable accurate and efficient genetic screening of embryos. Key instruments include next-generation sequencers (NGS), quantitative PCR (qPCR) systems, and fluorescence in situ hybridization (FISH) analyzers. NGS offers high-throughput sequencing capabilities and a broader detection range, making it suitable for detecting single-gene disorders and chromosomal abnormalities. Reagents and consumables used for PGT consist of various kits, probes, buffers, enzymes, and solutions necessary for genetic testing procedures. Probes are vital in detecting specific chromosomal aberrations, and buffers provide appropriate conditions for optimal amplification conditions. Software and services are essential components of PGT, as they ensure reliable data management, analysis, interpretation, and reporting for genetic testing results. Need-based preferences revolve around user-friendly interfaces, accurate algorithms for variant detection, comprehensive databases for variant annotation, and secure data storage options.

Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders

Preimplantation genetic diagnosis (PGD) is a specialized procedure that allows the identification of genetic mutations or chromosomal abnormalities in embryos diagnosed before implantation and pregnancy. The primary goal of PGD is to reduce the risk of developing specific genetic disorders such as cystic fibrosis, Huntington's disease, and muscular dystrophy. Preimplantation genetic screening (PGS), referred to as preimplantation genetic testing for aneuploidies (PGT-A), detects chromosomal aneuploidies or imbalances in embryos before implantation. PGS aims to improve the chances of successful pregnancies by identifying embryos with the correct number of chromosomes, reducing the risk of miscarriage, stillbirth, or having a child affected by Down syndrome or other chromosomal abnormalities.

Application: Wide use of preimplantation genetic testing for aneuploidy disorder

Aneuploidy is a disorder in which an abnormal number of chromosomes in a cell leads to genetic disorders, including Down syndrome, Edwards syndrome, and Patau syndrome. Preimplantation of genetic testing for aneuploidy (PGT-A) identifies embryos with chromosomal abnormalities before implantation, increasing the chances of a successful pregnancy outcome. Gender identification through preimplantation genetic testing allows couples to choose the gender of their child for family balancing or to avoid sex-linked disorders. Human leukocyte antigen (HLA) typing matches tissue types between donor and recipient for stem cell or organ transplantation procedures. Preimplantation HLA typing identifies embryos with compatible tissue types, potentially facilitating successful transplants in siblings with blood disorders or immune system deficiencies. Structural chromosomal abnormalities involve alterations in chromosome structure, including deletions, duplications, and rearrangements. In addition, X-linked diseases are caused by mutations in genes on the X chromosome, affecting males more severely than females.

End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments

Preimplantation genetics testing is widely used in various healthcare facilities, providing successful outcomes in clinical research. Contract research and manufacturing organizations (CRMOs) are primary organizations that play a crucial role in developing, manufacturing, and commercializing preimplantation genetic testing products. These organizations prefer outsourcing their services to ensure quality control, compliance with regulatory standards, and cost efficiency while focusing on their core competencies. Similarly, cryobanks are institutions that store biological samples such as sperm, eggs, and embryos at extremely low temperatures for future use. Preimplantation genetic testing is crucial for cryobanks to ensure the genetic viability of stored samples before implantation procedures like IVF or ICSI. Hospitals, diagnostic labs, and service providers contribute to patient care through accurate diagnosis and effective treatments using preimplantation genetic testing technologies. Research laboratories and academic institutes play a vital role in driving innovation and advancements in preimplantation genetic testing through cutting-edge research, technological developments, and interdisciplinary collaborations. These institutions focus on developing novel techniques like next-generation sequencing (NGS) to enhance the accuracy of preimplantation genetic testing methods.

Regional Insights

The Americas exhibit a high need for preimplantation genetic testing (PGT) owing to rising infertility rates caused by lifestyle changes and increasing awareness regarding genetic testing. Well-established healthcare infrastructure facilities and favorable reimbursement policies have made PGT services more accessible to couples seeking infertility treatments in the Americas. Companies in the region have strong R&D capabilities and government support that drive innovation in the field. Asia is emerging as a big and opportunistic market for PGT owing to improved provision of advanced fertility techniques such as IVF with PGT services and growing medical tourism, attracting international patients seeking cost-effective treatment options. Europe contributes significantly to the global PGT market due to factors such as increased government funding for healthcare research and widespread adoption of IVF procedures across various European countries. Moreover, stringent regulatory frameworks surrounding genetic testing ensure quality control and ethical considerations when implementing PGT services. Key players within this region contribute significantly to technological advancements in preimplantation genetic testing practices.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Preimplantation Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Preimplantation Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Preimplantation Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Comparative Genomic Hybridization
    • Fluorescence in-Situ Hybridization
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
    • Single-Nucleotide Polymorphism
  • Offering
    • Instruments
    • Reagents & Consumables
    • Software & Services
  • Procedure Type
    • Preimplantation Genetic Diagnosis
    • Preimplantation Genetic Screening
  • Application
    • Aneuploidy
    • Gender Identification
    • HLA Typing
    • Single Gene Disorders
    • Structural Chromosomal Abnormalities
      • Deletions
      • Duplications
      • Inversions
      • Translocations
    • X-Linked Disorders
  • End User
    • Contract Research & Manufacturing Organizations
    • Cryobanks
    • Hospitals, Diagnostic Labs, & Service Providers
    • Research Laboratories & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Preimplantation Genetic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Preimplantation Genetic Testing Market?

3. What are the technology trends and regulatory frameworks in the Preimplantation Genetic Testing Market?

4. What is the market share of the leading vendors in the Preimplantation Genetic Testing Market?

5. Which modes and strategic moves are suitable for entering the Preimplantation Genetic Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
      • 5.1.1.2. Increase in the rate of infertility and the rising number of fertility clinics worldwide
      • 5.1.1.3. Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Limitation and risks associated with PGT
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the field of preimplantation genetic analysis
      • 5.1.3.2. Emerging startup ecosystem and investments in the field of preimplantation genetic testing
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical constraints and Misuse of PGT
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders
    • 5.2.2. Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results
    • 5.2.3. Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders
    • 5.2.4. Application: Wide use of preimplantation genetic testing for aneuploidy disorder
    • 5.2.5. End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments
  • 5.3. Market Trend Analysis
    • 5.3.1. Presence of established companies and startups launching innovative preimplantation genetic solutions across the Americas
    • 5.3.2. Supportive Government initiatives and the increasing infertility rate emphasized preimplantation genetic testing adoption in APAC
    • 5.3.3. Rising adoption of preimplantation genetic testing for IVF across Europe and potential of global player expansion in Middle East & Africa
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Preimplantation Genetic Testing Market, by Technology

  • 6.1. Introduction
  • 6.2. Comparative Genomic Hybridization
  • 6.3. Fluorescence in-Situ Hybridization
  • 6.4. Next-Generation Sequencing
  • 6.5. Polymerase Chain Reaction
  • 6.6. Single-Nucleotide Polymorphism

7. Preimplantation Genetic Testing Market, by Offering

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Consumables
  • 7.4. Software & Services

8. Preimplantation Genetic Testing Market, by Procedure Type

  • 8.1. Introduction
  • 8.2. Preimplantation Genetic Diagnosis
  • 8.3. Preimplantation Genetic Screening

9. Preimplantation Genetic Testing Market, by Application

  • 9.1. Introduction
  • 9.2. Aneuploidy
  • 9.3. Gender Identification
  • 9.4. HLA Typing
  • 9.5. Single Gene Disorders
  • 9.6. Structural Chromosomal Abnormalities
  • 9.7. X-Linked Disorders

10. Preimplantation Genetic Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Contract Research & Manufacturing Organizations
  • 10.3. Cryobanks
  • 10.4. Hospitals, Diagnostic Labs, & Service Providers
  • 10.5. Research Laboratories & Academic Institutes

11. Americas Preimplantation Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Thermo Fisher Unveils Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit
    • 14.3.2. Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
    • 14.3.3. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
    • 14.3.4. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
    • 14.3.5. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
    • 14.3.6. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
    • 14.3.7. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
    • 14.3.8. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PREIMPLANTATION GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PREIMPLANTATION GENETIC TESTING MARKET DYNAMICS
  • FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GENDER IDENTIFICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GENDER IDENTIFICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HLA TYPING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DELETIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DELETIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DUPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DUPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INVERSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INVERSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TRANSLOCATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TRANSLOCATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY X-LINKED DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY X-LINKED DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CRYOBANKS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CRYOBANKS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, DIAGNOSTIC LABS, & SERVICE PROVIDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, DIAGNOSTIC LABS, & SERVICE PROVIDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 191. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 203. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 215. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 227. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 228. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 240. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 251. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 275. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
  • TABLE 287. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 288. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNO